Cover Image
市場調查報告書

全球癌症免疫療法市場預測

Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

出版商 GBI Research 商品編碼 410320
出版日期 內容資訊 英文 363 Pages
訂單完成後即時交付
價格
Back to Top
全球癌症免疫療法市場預測 Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market
出版日期: 2016年12月01日 內容資訊: 英文 363 Pages
簡介

癌症免疫療法市場,預計從2015年的169億美元,擴大到2022年的758億美元。預計市場2015年∼2022年以23.9%的年複合成長率成長。

本報告提供全球癌症免疫療法市場相關調查分析,主要上市產品,開發平台情形的評估,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 主要上市產品

  • 概要
  • Rituxan/MabThera
  • Revlimid (lenalidomide)
  • Yervoy (ipilimumab)
  • Opdivo (nivolumab)
  • Keytruda (pembrolizumab)
  • Pomalyst (pomalidomid)
  • Gardasil/Gardasil 9
  • Provenge (sipuleucel-T)
  • 結論

第4章 開發平台情形的評估

  • 概要
  • 開發平台開發情形
  • 開發平台的分子標的
  • 臨床實驗
  • 主要的開發中產品的評估

第5章 複數方案的市場預測

  • 綜合性的市場規模
  • 學名藥的普及
  • 收益預測:分子各標的
  • 收益與市場佔有率分析:各企業

第6章 企業分析與地位

  • 企業形勢
  • 上市、產品研發線分析

第7章 策略性整合

  • 許可證交易
  • 共同開發交易

第8章 附錄

目錄
Product Code: GBIHC418MR

Cancer is a group of diseases characterized by abnormal cell growth. It is a multi-step process, as a single mutation is almost certainly insufficient to cause a cell to become malignant. A number of cellular processes must be deregulated to allow cells to proliferate uncontrollably while evading apoptosis. Initially, key cell growth, proliferative and pro-apoptotic signaling pathways are deregulated in most cancers. These signaling pathways enable cell survival, continued proliferation, and the avoidance of programmed cell death.

Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patient's immune system in a general way or aiding the identification of specific antigens associated with the cancer. The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells.

The market size for cancer immunotherapies is expected to grow at an exceptional rate over the forecast period, from $16.9 Billion in 2015 to $75.8 Billion in 2022, at a compound annual growth rate (CAGR) of 23.9%. The forecast for the most optimistic outcome has the market reach $82.1 Billion in 2022, at a CAGR of 25.3%. The US market is forecast to grow at a similarly rapid rate, from $9.5 Billion in 2015 to $40.8 Billion in 2022, which equates to just over half of the total market size throughout the forecast period.

Overall, there are 2,037 products in active development in the cancer immunotherapy pipeline. This makes it a notable portion of the entire oncology pipeline, and reflects the strong interest in this class of therapy in product development. This is due to the growing clinical rationale behind developing such therapies, and the willingness of drug developers to invest in novel therapeutics, which will offer significant product differentiation from market competitors.

According to Yasser Mushtaq, "Although the cancer immunotherapy pipeline is clearly strong, a significant proportion is made up of early-stage products, namely those from the Discovery stage to Phase I. This is indicative of the difficulty associated with progressing cancer immunotherapies from preclinical laboratory studies to clinical application in humans."

The report "Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market" provides an introduction to key indications within cancer immunotherapies, including disease epidemiology, symptoms, pathophysiology, diagnosis and disease staging and prognosis.

In depth, it provides the following:

  • Provides an overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the cancer immunotherapies pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: breast cancer, melanoma, NSCLC and ovarian cancer.
  • Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan.
  • Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company's pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals, relating to cancer immunotherapy products.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Epidemiology
    • 2.2.1. Breast Cancer
    • 2.2.2. Melanoma
    • 2.2.3. Non-Small-Cell Lung Cancer
    • 2.2.4. Ovarian Cancer
  • 2.3. Pathophysiology and Etiology
    • 2.3.1. Breast Cancer
    • 2.3.2. Melanoma
    • 2.3.3. Non-Small-Cell Lung Cancer
    • 2.3.4. Ovarian Cancer
  • 2.4. Symptoms
    • 2.4.1. Breast Cancer
    • 2.4.2. Melanoma
    • 2.4.3. NSCLC
    • 2.4.4. Ovarian Cancer
  • 2.5. Diagnosis and Disease Staging
    • 2.5.1. Breast Cancer
    • 2.5.2. Melanoma
    • 2.5.3. Non-Small-Cell Lung Cancer
    • 2.5.4. Ovarian Cancer
  • 2.6. Prognosis
    • 2.6.1. Breast Cancer
    • 2.6.2. Melanoma
    • 2.6.3. Non-Small-Cell Lung Cancer
    • 2.6.4. Ovarian Cancer
  • 2.7. Treatment

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Rituxan/MabThera-Roche
  • 3.3. Revlimid (lenalidomide)-Celgene
  • 3.4. Yervoy (ipilimumab)-Bristol-Myers Squibb
  • 3.5. Opdivo (nivolumab)-Bristol-Myers Squibb
  • 3.6. Keytruda (pembrolizumab)-Merck & Co.
  • 3.7. Pomalyst (pomalidomid)-Celgene
  • 3.8. Gardasil/Gardasil 9(human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine-prophylactic vaccine)-Merck & Co.
  • 3.9. Provenge (sipuleucel-T)-Valeant Pharmaceuticals
  • 3.10. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.5. Conclusion
  • 4.5. Assessment of Key Pipeline Products
    • 4.5.1. Durvalumab-AstraZeneca
    • 4.5.2. Durvalumab + Tremelimumab-AstraZeneca
    • 4.5.3. Tisagenlecleucel-T (CTL-019)-Novartis
    • 4.5.4. KTE-C19-Kite Pharma
    • 4.5.5. Avelumab-Merck KGaA/Pfizer
    • 4.5.6. Epacadostat-Incyte Corporation
    • 4.5.7. Conclusion

5. Multi-scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Immune-Checkpoint Proteins
    • 5.3.2. Tumor Associated Antigens
    • 5.3.3. Cancer Vaccines
    • 5.3.4. Signal Transduction
  • 5.4. Revenue and Market Share Analysis by Company
    • 5.4.1. Celgene-Revlimid to Maintain Celgene's Position as Market Leader
    • 5.4.2. Bristol-Myers Squibb-Opdivo to Drive Revenue from Cancer Immunotherapies
    • 5.4.3. Roche-Revenue Generated from Cancer Immunotherapies Forecast to Grow due to Tecentriq and Gazyva
    • 5.4.4. Merck & Co.-Keytruda Key to Cancer Immunotherapy Market Growth
    • 5.4.5. AstraZeneca-New Approvals to Mark Entry of AstraZeneca in Cancer Immunotherapy Market
    • 5.4.6. Novartis-Cancer Immunotherapies Constitute Small Proportion of Vast Overall Revenue
    • 5.4.7. Amgen-Innovative Imlygic to Help Generate above $1 Billion from Cancer Immunotherapy Market
    • 5.4.8. Pfizer-Overall Cancer Immunotherapy Revenue to Surpass $1 Billion by 2022 due to PD-L1-Inhibitor Avelumab
    • 5.4.9. Kite Pharma-KTE-C19 CAR to Drive Revenue Growth in Forecast Period

6. Company Analysis and Positioning

  • 6.1. Company Landscape
  • 6.2. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deal by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Molecular Target and Value
    • 7.1.4. Table for Licensing Deals Valued above $500m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued above $100m

8. Appendix

  • 8.1. Bibliography
  • 8.2. All Pipeline Drugs by Phase of Development
    • 8.2.1. Discovery
    • 8.2.2. Preclinical
    • 8.2.3. IND/CTA-filed
    • 8.2.4. Phase I
    • 8.2.5. Phase II
    • 8.2.6. Phase III
    • 8.2.7. Pre-registration
    • 8.2.8. Unknown
  • 8.3. Abbreviations
  • 8.4. Disease List
  • 8.5. Methodology
    • 8.5.1. Coverage
    • 8.5.2. Secondary Research
    • 8.5.3. Market Size and Revenue Forecasts
    • 8.5.4. Pipeline Analysis
    • 8.5.5. Competitive Landscape
  • 8.6. Contact Us
  • 8.7. Disclaimer

List of Tables

  • Table 1: Cancer Immunotherapies Market, Global, Epidemiology of Key Oncology Indications, 2016
  • Table 2: Cancer Immunotherapies Market, Global, Regional Lymph Node and Metastasis Staging, 2016
  • Table 3: Cancer Immunotherapies Market, Global, Eastern Co-operative Oncology Group Criteria, 2016
  • Table 4: Cancer Immunotherapies Market, Global, Breast Cancer Histopathological and Molecular Classification, 2016
  • Table 5: Cancer Immunotherapies Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2016
  • Table 6: Cancer Immunotherapies Market, US, Ovarian Cancer Stage and Survival Rates (%), 2016
  • Table 7: Cancer Immunotherapies Market, US, Lung Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2016
  • Table 8: Cancer Immunotherapies Market, US, Ovarian Cancer Stage at Diagnosis and Five-year Relative Survival (%), 2016
  • Table 9: Cancer Immunotherapies Market, Global, Approved Indications for Rituxan, 2016
  • Table 10: Cancer Immunotherapies Market, Global, Approved Indications for Revlimid, 2016
  • Table 11: Cancer Immunotherapies Market, Global, Approved Indications for Yervoy, 2016
  • Table 12: Cancer Immunotherapies Market, Global, Approved Indications for Opdivo, 2016
  • Table 13: Cancer Immunotherapies Market, Global, Approved Indications for Keytruda, 2016
  • Table 14: Cancer Immunotherapies Market, Global, Approved Indications for Pomalyst, 2016
  • Table 15: Cancer Immunotherapies Market, Global, Approved Indications for Gardasil, 2016
  • Table 16: Cancer Immunotherapies Market, Global, Approved Indications for Provenge, 2016
  • Table 17: Cancer Immunotherapies Market, Global, Forecast Revenue by Company, 2016
  • Table 18: Cancer Immunotherapies Market, Global, Licensing Deals Valued above $500m, 2006-2016
  • Table 19: Cancer Immunotherapies Market, Global, Co-development Deals Valued above $100m, 2006-2016
  • Table 20: Cancer Immunotherapies Market, Global, Pipeline Products, Discovery, 2016
  • Table 21: Cancer Immunotherapies Market, Global, Pipeline Products, Preclinical, 2016
  • Table 22: Cancer Immunotherapies Market, Global, Pipeline Products, IND/CTA filed, 2016
  • Table 23: Cancer Immunotherapies Market, Global, Pipeline Products, Phase I, 2016
  • Table 24: Cancer Immunotherapies Market, Global, Pipeline Products, Phase II, 2016
  • Table 25: Cancer Immunotherapies Market, Global, Pipeline Products, Phase III, 2016
  • Table 26: Cancer Immunotherapies Market, Global, Pipeline Products, Pre-Registration, 2016
  • Table 27: Cancer Immunotherapies Market, Global, Pipeline Products, Unknown, 2016

List of Figures

  • Figure 1: Cancer Immunotherapies Market, Global, Epidemiology Patterns for Breast Cancer, 2015-2023
  • Figure 2: Cancer Immunotherapies Market, Global, Epidemiology Patterns for Melanoma, 2015-2023
  • Figure 3: Cancer Immunotherapies Market, Global, Epidemiology Patterns for NSCLC, 2015-2023
  • Figure 4: Cancer Immunotherapies Market, Global, Epidemiology Patterns for Ovarian Cancer, 2015-2023
  • Figure 5: Cancer Immunotherapies Market, Global, NSCLC Molecular Characteristic Frequency (%)
  • Figure 6: Cancer Immunotherapies Market, Global, Key Marketed Products and Approved Indications, 2016
  • Figure 7: Cancer Immunotherapies Market, Global, Annual Revenue for Rituxan ($bn), 2006-2022
  • Figure 8: Cancer Immunotherapies Market, Global, Annual Revenue for Revlimid ($bn), 2006-2022
  • Figure 9: Cancer Immunotherapies Market, Global, Annual Revenue for Yervoy ($bn), 2011-2022
  • Figure 10: Cancer Immunotherapies Market, Global, Annual Revenue for Opdivo ($bn), 2014-2022
  • Figure 11: Cancer Immunotherapies Market, Global, Annual Revenue for Keytruda ($bn), 2014-2022
  • Figure 12: Cancer Immunotherapies Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2022
  • Figure 13: Cancer Immunotherapies Market, Global, Annual Revenue for Gardasil ($bn), 2006-2022
  • Figure 14: Cancer Immunotherapies Market, Global, Annual Revenue for Provenge ($m), 2010-2022
  • Figure 15: Cancer Immunotherapies Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
  • Figure 16: Cancer Immunotherapies Market, Global, Pipeline for Cancer Immunotherapies by Stage of Development, Molecule Type and Program Type, 2016
  • Figure 17: Cancer Immunotherapies Market, Global, Pipeline for Key Cancers by Stage of Development, 2016
  • Figure 18: Cancer Immunotherapies Market, Global, Pipeline for Key Cancers by Molecule Type, 2016
  • Figure 19: Cancer Immunotherapies Market, Global, Pipeline for Cancer Immunotherapies by Molecular Target, 2016
  • Figure 20: Cancer Immunotherapies Market, Global, Pipeline for Key Cancers by Molecular Target, 2016
  • Figure 21: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
  • Figure 22: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
  • Figure 23: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 24: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 25: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
  • Figure 26: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
  • Figure 27: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
  • Figure 28: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
  • Figure 29: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
  • Figure 30: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 31: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 32: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 33: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016
  • Figure 34: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 35: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 36: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 37: Cancer Immunotherapies Market, Global, Revenue for Durvalumab ($bn), 2017-2022
  • Figure 38: Cancer Immunotherapies Market, Global, Revenue for Durvalumab and Tremelimumab ($bn), 2018-2022
  • Figure 39: Cancer Immunotherapies Market, Global, Revenue for Tisagenlecleucel-T ($bn), 2017-2022
  • Figure 40: Cancer Immunotherapies Market, Global, Revenue for KTE-C19 ($m), 2017-2022
  • Figure 41: Cancer Immunotherapies Market, Global, Revenue for Avelumab ($m), 2017-2022
  • Figure 42: Cancer Immunotherapies Market, Global, Revenue for Epacadostat ($m), 2018-2022
  • Figure 43: Cancer Immunotherapies Market, Global, Market Size ($bn), 2015-2022
  • Figure 44: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
  • Figure 45: Cancer Immunotherapies Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022
  • Figure 46: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune-Checkpoint Proteins ($bn), 2015-2022
  • Figure 47: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2015-2022
  • Figure 48: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Cancer Vaccines ($bn), 2015-2022
  • Figure 49: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Signal Transduction ($bn), 2015-2022
  • Figure 50: Cancer Immunotherapies Market, Global, Company Analysis Matrix, 2015-2022
  • Figure 51: Cancer Immunotherapies Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 52: Cancer Immunotherapies Market, Global, Companies by Compound Annual Growth Rate (%), Base Year-2022
  • Figure 53: Cancer Immunotherapies Market, Global, Revenue by Product Type, 2015-2022
  • Figure 54: Cancer Immunotherapies Market, Global, Celgene Annual Revenue Forecast ($bn), 2015-2022
  • Figure 55: Cancer Immunotherapies Market, Global, Bristol-Myers Squibb Annual Revenue ($bn), 2015-2022
  • Figure 56: Cancer Immunotherapies Market, Global, Roche Annual Revenue ($bn), 2015-2022
  • Figure 57: Cancer Immunotherapies Market, Global, Merck & Co. Annual Revenue ($bn), 2015-2022
  • Figure 58: Cancer Immunotherapies Market, Global, AstraZeneca Annual Revenue ($bn), 2017-2022
  • Figure 59: Cancer Immunotherapies Market, Global, Novartis Annual Revenue ($bn), 2015-2022
  • Figure 60: Cancer Immunotherapies Market, Global, Amgen Annual Revenue ($bn), 2015-2022
  • Figure 61: Cancer Immunotherapies Market, Global, Pfizer Annual Revenue ($bn), 2016-2022
  • Figure 62: Cancer Immunotherapies Market, Global, Kite Pharma Annual Revenue ($m), 2017-2022
  • Figure 63: Cancer Immunotherapies Market, Global, Cluster by Growth and Market Share, 2015-2022
  • Figure 64: Cancer Immunotherapies Market, Global, Companies by Type, 2016
  • Figure 65: Cancer Immunotherapies Market, Global, High-Activity and Late-Stage Developers by Level of Specialization, 2016
  • Figure 66: Cancer Immunotherapies Market, Global, Proportion of Total Company Revenue Attributed to Cancer Immunotherapies, 2015-2022
  • Figure 67: Cancer Immunotherapies Market, Global, Licensing Deals by Region, Year and Value, 2006-2016
  • Figure 68: Cancer Immunotherapies Market, Global, Licensing Deals by Indication and Value, 2006-2016
  • Figure 69: Cancer Immunotherapies Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
  • Figure 70: Cancer Immunotherapies Market, Global, Licensing Deals by Molecule Type and Target, 2006-2016
  • Figure 71: Cancer Immunotherapies Market, Global, Co-development Deals by Region, Year and Value, 2006-2016
  • Figure 72: Cancer Immunotherapies Market, Global, Co-development Deals by Indication, 2006-2016
  • Figure 73: Cancer Immunotherapies Market, Global, Co-development Deals by Stage of Development and Value, 2006-2016
  • Figure 74: Cancer Immunotherapies Market, Global, Co-development Deals by Molecule Type and Target, 2006-2016
Back to Top